The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research.
The human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic is of unprecedented gravity and is spreading rapidly, notably in the most disadvantaged regions of the world. The search for a preventive vaccine is thus an absolute priority. For over 10 years the French National Agency for AIDS research (ANRS) has been committed to an original program combining basic science and clinical research. The HIV preventive vaccine research program run by the ANRS covers upstream research for the definition of immunogens, animal models, and clinical research to evaluate candidate vaccines. Most researchers in 2004 believe that it should be possible to obtain partial vaccine protection through the induction of a strong and multiepitopic cellular response. Since 1992, the ANRS has set up 15 phases I and II clinical trials in order to evaluate the safety and the capacity of the candidate vaccines for inducing cellular immune responses. The tested candidate vaccines were increasingly complex recombinant canarypox viruses (Alvac) containing sequences coding for certain viral proteins, utilized alone or combined with other immunogens (whole or truncated envelope proteins). ANRS has also been developing an original strategy based on the utilization of lipopeptides. These comprise synthetic fragments of viral proteins associated with lipids that facilitate the induction of a cellular immune response. These approaches promptly allowed the assessment of a prime-boost strategy combining a viral vector and lipopeptides.
Fischer
Elizabeth
E
Agence Nationale de Recherches sur le SIDA, 101 rue de Tolbiac, 75013 Paris, France. elizabeth.fischer@anrs.fr
Rieux
Véronique
V
Guillet
Jean-Gérard
JG
Kazatchkine
Michel
M
D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D028121:Canarypox virus / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005602:France; D005822:Genetic Vectors / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008074:Lipoproteins / Q000276:immunology*
D016915:AIDS Vaccines; D008074:Lipoproteins